FLUCELVAX, FLUCELVAX QUADRIVALENT Drug Profile

Summary for Tradename: FLUCELVAX, FLUCELVAX QUADRIVALENT

High Confidence Patents:	4
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for FLUCELVAX, FLUCELVAX QUADRIVALENT Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for FLUCELVAX, FLUCELVAX QUADRIVALENT Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Seqirus Inc.	FLUCELVAX, FLUCELVAX QUADRIVALENT	influenza vaccine	Injection	125408		2040-10-16	DrugPatentWatch analysis and company disclosures
Seqirus Inc.	FLUCELVAX, FLUCELVAX QUADRIVALENT	influenza vaccine	Injection	125408		2039-03-11	DrugPatentWatch analysis and company disclosures
Seqirus Inc.	FLUCELVAX, FLUCELVAX QUADRIVALENT	influenza vaccine	Injection	125408		2041-01-19	DrugPatentWatch analysis and company disclosures
Seqirus Inc.	FLUCELVAX, FLUCELVAX QUADRIVALENT	influenza vaccine	Injection	125408		2022-07-12	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for FLUCELVAX, FLUCELVAX QUADRIVALENT Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Seqirus Inc.	FLUCELVAX, FLUCELVAX QUADRIVALENT	influenza vaccine	Injection	125408		2036-10-12	Patent claims search
Seqirus Inc.	FLUCELVAX, FLUCELVAX QUADRIVALENT	influenza vaccine	Injection	125408		2034-01-23	Patent claims search
Seqirus Inc.	FLUCELVAX, FLUCELVAX QUADRIVALENT	influenza vaccine	Injection	125408		2034-09-23	Patent claims search
Seqirus Inc.	FLUCELVAX, FLUCELVAX QUADRIVALENT	influenza vaccine	Injection	125408		2035-08-03	Patent claims search

International Patents for FLUCELVAX, FLUCELVAX QUADRIVALENT

Country	Patent Number	Estimated Expiration
European Patent Office	1945253
Eurasian Patent Organization	036992
Japan	2009514838
Canada	2907149

Supplementary Protection Certificates for FLUCELVAX, FLUCELVAX QUADRIVALENT

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
122020000047	Germany		PRODUCT NAME: INFLUENZAVIRUS-HAEMAGGLUTININ, INAKTIVIERT, DER FOLGENDEN STAEMME HERGESTELLT IN ZELLKULTUR: B/XXXXX - AEHNLICHER STAMM B/XXXXX - AEHNLICHER STAMM; REGISTRATION NO/DATE: EU/1/18/1326 20181212
CA 2024 00037	Denmark		PRODUCT NAME: INFLUENZA A VIRUS H5 HAEMAGGLUTININ OVERFLADEANTIGEN, INAKTIVERET, FREMSTILLET I CELLEKULTURER; REG. NO/DATE: EU/1/24/1806, EU/1/24/1807 20240422
C20240033	Finland
122024000055	Germany		PRODUCT NAME: INFLUENZA-A-VIRUS-H5-HAEMAGGLUTININ-OBERFLAECHENANTIGEN, INAKTIVIERT, HERGESTELLT IN ZELLKULTUREN; REGISTRATION NO/DATE: EU/1/24/1806 20240419

Market Dynamics and Financial Trajectory for Flucelvax and Flucelvax Quadrivalent

Last updated: April 21, 2026

What are Flucelvax and Flucelvax Quadrivalent?

Flucelvax (cell-based influenza vaccine) is developed by Seqirus, a CSL company. It is approved in various markets primarily for seasonal influenza prevention. Flucelvax Quadrivalent extends the formulation to cover four influenza strains, offering broader protection.

• Flucelvax (trivalent): Approved in the U.S. since 2016; includes two influenza A strains, one influenza B strain.
• Flucelvax Quadrivalent (quadrivalent): Approved in the U.S. since 2018; includes four strains, adding an extra B strain.

Market Size and Growth Drivers

The global influenza vaccine market was valued at approximately USD 4.2 billion in 2022. It is expected to grow at a CAGR of around 6% through 2028, reaching USD 6.1 billion.

Key factors influencing growth:

• Increased demand for cell-based vaccines as alternatives to egg-based options.
• High vaccination rates in developed countries.
• Ongoing pandemic preparedness initiatives.
• Expansion into emerging markets with targeted immunization programs.

Market Share and Competitive Position

Seqirus holds roughly 20-25% of the global influenza vaccine market, ranking second after Sanofi Pasteur. Flucelvax's share is concentrated in North America and Europe, driven by approval status and manufacturer distribution capabilities.

Competitor	Product	Market Share (approx.)	Key Differentiators
Sanofi Pasteur	Fluzone, Flublok	50%	Egg-based and recombinant options
Seqirus	Flucelvax, Flucelvax Qu	20-25%	Cell-based technology, quadrivalent
AstraZeneca	FluMist (nasal)	10%	Live attenuated vaccine

Regulatory and Policy Landscape

Major health authorities have approved cell-based influenza vaccines:

• U.S. FDA: Approved Flucelvax since 2016; Flucelvax Quadrivalent since 2018.
• European Medicines Agency (EMA): Approved Flucelvax and Flucelvax Quadrivalent.
• Japan: Approved Flucelvax in 2020, expanding market access.

Policy shifts favor immunization strategies that reduce egg-based vaccine risks:

• Cell-based vaccines circumvent egg-adaptive mutations.
• Increased funding for pandemic preparedness enhances demand.

Production Capacity and Supply Chain Dynamics

Seqirus operates multiple manufacturing facilities with an annual capacity estimated at approximately 150 million doses for Flucelvax and Flucelvax Quadrivalent combined. Supply hinges on:

• Seasonal demand fluctuations.
• Pandemic-related stockpiling.
• Regulatory approvals in new markets.

Seasonality affects sales peaks in Q3 and Q4, aligning with hemisphere-specific influenza seasons.

Financial Trajectory and Revenue Projections

Estimated global sales for Flucelvax and Flucelvax Quadrivalent combined were approximately USD 800 million in 2022. Projected revenues are expected to grow beyond USD 1.2 billion by 2028, assuming:

• Continued market penetration.
• Expansion into additional regions like Asia-Pacific.
• Successful regulatory approvals of new formulations or indications.

Factors influencing revenue growth include:

• Increasing vaccine coverage in pediatric, adult, and high-risk groups.
• Introduction of co-formulations or multiplexed vaccines.
• Competitive pressure from other cell-based and recombinant vaccines.

Risks and Challenges

• Vaccine hesitancy impacting uptake.
• Regulatory delays in emerging markets.
• Manufacturing disruptions due to supply chain issues.
• Price pressures amid rising healthcare costs.

Key Takeaways

• Flucelvax and Flucelvax Quadrivalent operate in a growing, competitive influenza vaccine market.
• Market growth is driven by increased adoption of cell-based vaccines and pandemic preparedness initiatives.
• Revenue projections suggest substantial growth potential, especially with expanded global approval and increased vaccination coverage.
• Manufacturing capacity and supply chain stability are critical factors for growth continuity.
• Competitive pressures from egg-based and recombinant vaccines influence market share dynamics.

Frequently Asked Questions

Q1: What differentiates Flucelvax from traditional egg-based influenza vaccines?
Cell-based manufacturing reduces egg-adaptive mutations, resulting in more accurate strain matching and potentially higher efficacy.

Q2: How do Flucelvax and Flucelvax Quadrivalent compare in market penetration?
The quadrivalent version has broader strain coverage, leading to increased adoption in markets prioritizing comprehensive immunization.

Q3: What are the primary regions driving sales expansion?
North America, Europe, and select Asia-Pacific markets, contingent on regulatory approvals and vaccination programs.

Q4: What are the main risks for Flucelvax's financial growth?
Regulatory delays, manufacturing capacity constraints, competition from recombinant vaccines, and vaccine hesitancy.

Q5: How does pandemic preparedness influence the influenza vaccine market?
It increases demand for stockpiling vaccines and accelerates approval pathways, bolstering sales and strategic positioning.

---

References

1. Pharmaceutical Technology. (2023). Influenza vaccines market analysis.
2. Statista. (2023). Global influenza vaccine market forecast.
3. U.S. Food and Drug Administration. (2016, 2018). Approvals for Flucelvax and Flucelvax Quadrivalent.
4. European Medicines Agency. (2022). Approved influenza vaccines.
5. Seqirus. (2022). Corporate annual report.